JAB-30355

· Jacobio Pharmaceuticals Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JAB-30355, covering 2026-01-22 to 2026-01-22. Get the full timeline:

Most recent: Clinical Trial Update: JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation [Phase 1, Phase 2]